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ABSTRACT 
It is now more than a year since the first case of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) disease 
(COVID-19) was diagnosed in China. Current data suggest that pregnancy may not only be a risk factor for the develop-
ment of severe forms of COVID-19, but that the SARS-CoV-2 infection may impact on common pregnancy complications 
as well. Healthy pregnant women are likely to be more susceptible to viral infection and therefore are at higher risk of de-
veloping severe COVID-19 because of adaptive changes in their immune and respiratory systems, their altered endothelial 
cell functions, and modified coagulation responses. However, studies show that most pregnant women diagnosed with 
COVID-19 developed mild-to-moderate symptoms and only a few of them have required critical care facilities. In contrast 
with preeclampsia, preeclampsia-like syndrome can resolve spontaneously following recovery from severe pneumonia 
and may not be an obstetric indication for delivery. Preeclampsia-like syndrome is one symptom of COVID-19, but its 
cause is different from obstetric preeclampsia and therefore not connected with placental failure. Vertical transmission 
of SARS-CoV-2 infection is rare but can probably occur. No evidence has been found that COVID-19 developed during  
pregnancy leads to unfavourable outcomes in the fetus. Most health authorities indicate that standard procedures  
should be used when managing pregnancy complications in asymptomatic women with confirmed SARS-CoV-2. Vaccines 
should not be withheld from pregnant and lactating individuals who otherwise meet the vaccination criteria.
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INTRODUCTION
It is now more than a year since the first case of Severe 
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) 
disease (COVID-19) was diagnosed in China. As of 14 March 
2021 there have been over 120.3 million cases and about 
2.6 million deaths reported globally since the start of the 
pandemic [1]. In Poland by the same date, there had been 
1.9 million confirmed cases of COVID-19 and 47,178 deaths 
[2]. As the numbers of COVID-19 cases, hospitalizations, and 
deaths all continue to rise across the world, it is paramount 
for clinicians to be up to date with the most recent infor-
mation on the course and treatment of this novel disease. 
By reviewing the most recent studies on maternal and fetal 
outcomes among COVID-19 diagnosed women from around 
the world, our study seeks to determine whether pregnant 
women are more likely to develop severe forms of COVID 
compared with non-pregnant women, and whether preg-
nant women affected by COVID during pregnancy are more 
likely to develop common obstetric complications, such as 
preterm birth, preeclampsia, caesarean section, and oth-
ers. We will also make clinical recommendations based on 
our analysis of the literature. 
SUSCepTIBIlITy TO SARS-COV-2  
DURINg pRegNANCy AND SympTOmS OF 
COVID-19 AmONg pRegNANT WOmeN
According to data published over the past year, healthy 
pregnant women are likely to be more susceptible to 
SARS-CoV-2 infection than non-pregnant women. This is 
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most probably due to adaptive changes in the woman’s im-
mune system during pregnancy, resulting in altered immune 
responses to infections during pregnancy [3–5]. In addition, 
there are several anatomical changes that take place in the 
pregnant woman’s respiratory system. A reduction in chest 
volume leads to decreased functional residual capacity, 
end-expiratory volumes, and residual volumes. These further 
result in a reduction of total lung capacity and an inability 
to clear secretions. These are the most significant factors 
that can make pregnant women more-than-otherwise sus-
ceptible to severe respiratory infections, including Corona-
virus disease 2019 (COVID-19) [6]. Another important issue 
is the possibility of additive or synergistic risk factors for 
thrombosis in pregnant women affected with COVID-19. 
It is already established that COVID-19 is associated with 
high rates of thromboembolic complications [7]. Due to vari-
ous changes in the coagulation response during pregnancy, 
which include increased thrombin production, increased in-
travascular inflammation and higher levels of plasminogen, 
pregnant women are at an increased risk of thromboembolic 
events [8, 9]. In light of the above, current guidelines suggest 
that all pregnant woman diagnosed with COVID-19 should 
have thromboprophylaxis postnatally until the 10th day [10]. 
Emerging evidence suggests that endothelial cell dys-
function plays a significant role in the onset and progression 
of acute respiratory distress syndrome [11], which is the 
main cause of mortality in COVID-19 [12–14]. Endothelial cell 
dysfunction is also observed in women with preeclampsia 
[15]. These data may suggest that this group is at a higher 
risk of developing severe COVID-19 [16]. 
ImpACT OF SARS-COV-2 ON pRegNANCy
Since January 2020, several studies have described 
the presentation and clinical course of COVID-19 in preg-
nancy. Up till now it appears that pregnant women are not 
at an increased risk of developing severe COVID-19 [17]. 
Wastnedge et al., reviewed data from 31 studies with quite 
reassuring results. Of more than 12,000 pregnant women 
with COVID-19 diagnosed, the majority developed mild to 
moderate symptoms, and only few women required criti-
cal care facilities. In the same review, the authors found 
that overall, 146 deaths had been reported. Severe compli-
cations of COVID-19 during pregnancy are rare but these 
can occur. Pre-existing comorbidities, advanced maternal 
age, and high body mass index seem to be risk factors for 
severe COVID-19 [18]. Based on the collected data, less 
than 10% of infected pregnant women required admission 
to an intensive care unit [19]. Most of those admitted to 
ICU suffered from pneumonia, acute respiratory distress 
syndrome (ARDS), or multiple organ dysfunction syndrome 
(MODS) [20–22].
COVID-19 AND hypeRTeNSIVe DISORDeRS 
IN pRegNANCy
Hypertensive disorders are the most common medical 
complications of pregnancy and a major cause of mater-
nal and perinatal morbidity and death. Detecting elevated 
blood pressure during pregnancy is one of the cardinal 
aspects of optimal antenatal care. With the outbreak of novel 
coronavirus-19 disease important is to check all COVID-19 di-
agnosed pregnant women for hypertensive disorders [7]. 
Mendoza et al. [23], carried out an observational study 
in which they found some features of preeclampsia (PE) in 
women with COVID-19 infection. Although there is a vari-
ant pathomechanism between actual preeclampsia and 
preeclampsia connected with SARS-CoV-2, it can be difficult 
to differentiate based on clinical symptoms. Detailed labora-
tory assessment, including angiogenic factors can be helpful 
in distinguishing between the two conditions. PE-like syn-
drome, in contrast to preeclampsia, can resolve spontane-
ously after recovery from severe pneumonia and may not 
be an obstetric indication for delivery. PE-like syndrome is 
a symptom of COVID-19, and not connected with placental 
failure.
VeRTICAl TRANSmISSION OF SARS-COV-2
Among studies that include neonatal test results for 
SARS-CoV-2, only a few of them report COVID-19 positive 
cases [7, 24, 25]. It remains unclear whether infection occurs 
in utero, or during labour, or at birth as the tests have mostly 
used polymerase chain reaction (PCR)-based methods. More 
evidence is required on this subject, especially in terms of 
routine PCR and antibody testing in neonates.
eFFeCTS OF VIRAl INFeCTION ON The FeTUS
In the majority of the studies reporting on neonatal 
outcomes, no serious adverse outcomes in the neonates 
born to SARS-CoV-2 positive mothers have been observed 
[17]. Available data comparing the neonatal outcomes in 
a group of symptomatic COVID-19 mothers with those of 
symptomatic non-COVID-19 mothers, found no significant 
differences in the rates of adverse neonatal outcomes [26].
meDICAl heAlTh AUThORITy gUIDelINeS
The American College of Obstetricians and Gynaecolo-
gists (ACOG), the Royal College of Obstetricians and Gynae-
cologists (RCOG) and the Polish Society of Gynaecologists 
and Obstetricians (PTGiP) recommend testing all pregnant 
women admitted to hospital, and not only those with COVID- 
-19 symptoms, due to the asymptomatic course of the dis-
ease. Treatment of typical diseases during pregnancy in 
asymptomatic patients with COVID-19 should be carried 
out using standard procedures. However, if a patient has 
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dyspnoea, fever, a deterioration in their general condition, 
they may require some or all of these additional treatments: 
oxygen therapy, antibiotics, steroid therapy, and thrombo-
prophylaxis. Mode of delivery will depend on obstetric indi-
cations. COVID-19 is not an indication for caesarean section 
itself unless the symptoms of COVID-19 cause the woman’s 
condition to deteriorate [27, 28].
According to most medical health authorities, includ-
ing the World Health Organization (WHO), RCOG, ACOG, 
and the Centers for Disease Control and Prevention (CDC), 
COVID-19 is not a contraindication for breastfeeding, which 
is recommended for all women who wish to breastfeed. 
Up till now, there is no evidence of serious adverse events 
in neonates, therefore patients with confirmed SARS-CoV-2 
infection should be encouraged to continue breastfeeding, 
while taking adequate precautions to prevent transmission 
of the virus to the baby [27–29]. According to the Polish 
Neonatal Society, and the National Perinatology Consultant 
in accord with the National Infectious Diseases Consultant, 
breastfeeding is recommended to all women who wish 
to breastfeed. It is only contraindicated when the general 
condition of the mother or the baby requires medical as-
sistance. The decision to breastfeed is left to the mother 
following a documented written informed consent process 
has been completed prior to childbirth, where the possible 
risks and benefits of breastfeeding for the neonate as well 
as the negative impact of isolation on the mother are made 
clear [30].
Vaccination in pregnant women
Specific clinical trials of COVID-19 vaccines in pregnant 
women have not yet been carried out. Worldwide, there are 
numerous discrepancies between local guidelines regarding 
the safety of COVID-19 vaccines during pregnancy. According 
to the ACOG, COVID-19 vaccines should not be withheld from 
pregnant and lactating individuals who meet the criteria for 
vaccination based on the Advisory Committee on Immuniza-
tion Practices (ACIP) [28]. According to the RCOG, vaccina-
tion can be discussed with pregnant and / or breastfeeding 
women if they are clinically in an extremely vulnerable group 
or if they are frontline health or social care workers, includ-
ing working in a residential care facility [27, 31]. In Poland, 
the PTGiP emphasises that pregnant women with active 
COVID-19 are burdened with a higher risk of severe disease 
but the authority has not yet released a statement about 
vaccination [32]. According to the Danish Health Authority, 
pregnant or breastfeeding women will not be offered vac-
cination. However, in exceptional cases, for example in the 
presence of severe chronic diseases, a pregnant woman may 
be offered a vaccination based on an individual medical as-
sessment [33]. According to the Health Service Executive in 
Ireland (HSE), pregnant and breastfeeding women should 
receive a COVID-19 vaccine when it is available to them; and 
the first dose should be given no sooner than 14 gestational 
weeks, and the second dose should be given before the 
end of 34 weeks of gestation [34]. The Swiss Bundesamt für 
Gesundheit (BAG) and Belgium’s Superior Health Council do 
not recommend COVID-19 vaccination for pregnant women. 
Only those women with specific chronic diseases should 
be considered on a case-by-case basis [35, 36]. The most 
recent data presented by Mullins et al., based on a group of 
4,005 pregnant women with either suspected or confirmed 
SARS-CoV-2 infection, has indicated the need for enhanced 
precautions to prevent SARS-CoV-2 infection in pregnancy, 
particularly in the context of the increased risks of preterm 
delivery and maternal mortality, and the need for priority 
vaccination of women planning pregnancy [37]. 
SUmmARy 
Scientists are constantly expanding our understanding 
of COVID-19. Due to relative lack of experience with the 
novel disease, both pregnant women and obstetricians 
all around the world became anxious about the impact of 
SARS-CoV-2 infection on pregnancy outcomes. The above 
review is reassuring, showing that in most pregnant women, 
COVID-19 is not likely to become a severe life-threatening 
condition, neither for the mother nor for the neonate. The 
most recent treatment recommendations include the saf-
est procedures for pregnant women, mothers, and their 
children immediately following delivery.
There are still many unknowns that require further study. 
Firstly, any mechanism of vertical transmission should be 
identified if such exists. In addition, it is paramount to dis-
cover whether infection during pregnancy is likely to lead 
to any long-term adverse effects in offspring, and whether 
such effects are dependent on gestational age at time of 
infection. Therefore, a database of all infected pregnant 
woman should be established and made available for fur-
ther investigations and follow-up studies. 
Finally, scientists should be urged to include pregnant 
women in the clinical trials of new treatment methods and 
prophylaxis in order to establish the safety of these methods 
for this particular group. 
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